Thirty consecutive patients who underwent stent implantation (the CoCr-EES [XIENCE Alpine™; Abbott Vascular, Santa Clara, CA, USA], N = 10; BP-EES [Synergy™; Boston Scientific Corporation, Marlborough, MA, USA], N = 10; and BP-SES [Ultimaster™; Terumo Corp., Tokyo, Japan], N = 10) for acute coronary syndrome (ACS) were prospectively enrolled. Patients had ischemic chest discomfort with ST-segment elevation or depression of >0.5 mm or T-wave inversion in 2 or more leads. Acute myocardial infarction was diagnosed by increased troponin T levels, serum levels of creatine phosphokinase (more than twice the upper limit of normal), and creatine phosphokinase-MB fraction (>10% of the total creatine kinase). Patients without elevation of the creatine kinase-MB fraction were classified as having unstable angina.
Patients with the following criteria were excluded: cardiogenic shock, left main coronary artery disease, extremely tortuous or heavily calcified vessels, intolerance to antiplatelet drugs, in-stent restenosis after DES implantation, overlapped stenting, multiple stenting, and severe chronic kidney disease (estimated glomerular filtration rate < 30 mL/min/1.73 m2).
Patients with the following criteria were excluded: cardiogenic shock, left main coronary artery disease, extremely tortuous or heavily calcified vessels, intolerance to antiplatelet drugs, in-stent restenosis after DES implantation, overlapped stenting, multiple stenting, and severe chronic kidney disease (estimated glomerular filtration rate < 30 mL/min/1.73 m2).